Latest Content

The XpertHCV test from Cepheid enables rapid, point-of-care detection of hepatitis C infection in under an hour—helping to expand access to care and reduces follow-up loss.

At IDWeek, Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, discussed the 96-week results from the PASO DOBLE study and the preliminary long-acting injectable PrEP results from the CLARITY study.

Ashlan Kunz Coyne, PharmD, MPH, discusses the potential of combining antibiotics with phage mixture therapy in treating these types of infections.

George Sakoulas, MD, discusses how transitioning pneumonia patients from IV to oral therapy after 3 to 4 days of clinical stability supports effective 7-day treatment courses, while patients who are immunocompromised and those with Pseudomonas infections require individualized, extended management.

Sustained HIV/syphilis elimination of mother-to-child transmission (EMTCT) since 2019 and new hepatitis B validation reflect high antenatal screening, >95% HBV birth-dose coverage, and integrated maternal–child health services.

The 2025 report from the WHO Global Antibiotic Resistance Surveillance System (GLASS) calls for urgent action against increasing threat of AMR. This is part 2 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance System Report 2025.

The Global Antimicrobial Resistance and Use Surveillance System (GLASS) of the WHO finds antibiotic resistance and the particular threat of resistant Gram-negative bacteria disproportionately prevalent in low- and middle-income countries. Here is part 1 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance Report.

This week, meet SIDP's president-elect, the connection between UTIs and meat, a COVID-19 vaccine alternative, and other highlights from IDWeek.

A new genomic study reveals that up to 18% of urinary tract infections (UTIs) in Southern California may stem from E coli strains transmitted through contaminated poultry and meat, disproportionately affecting residents of low-income neighborhoods.

Ed J Kuijper, MD, PhD details who is at highest risk for rCDI, how to interpret NAAT–toxin results, and how to sequence fidaxomicin, vancomycin, and microbiota-based therapies.

Moderna’s investigational cytomegalovirus (CMV) vaccine, mRNA-1647, did not meet its primary endpoint in a phase 3 trial, leading the company to discontinue its congenital CMV program while continuing studies in transplant patients.

Dumkow discusses her goals for her tenure as well as professional societies' roles in public health advocacy and AI.

At IDWeek, the company reported promising phase 1/2 trial results for its shingles vaccine candidate Z-1018, demonstrating strong immune responses and favorable tolerability.